Projects

Mgr. Lucia Kučerová, DrSc.

International

Finished
  • INNOVATIVE PARTNERSHIP FOR ACTION AGAINST CANCER
    Program: Other
    Duration: 1. 4. 2018 – 31. 12. 2021
  • Innovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by a Novel Combination of Epigenetic and Anticancer Drugs with Gene Therapy
    Program: ERANET
    Duration: 1. 1. 2017 – 30. 6. 2021
  • Role of IL-6/NF-κB /HIF-1 axis in adipose tissue mesenchymal stromal cells-mediated breast cancer cells stemness
    Program: Bilateral - other
    Duration: 1. 1. 2017 – 31. 12. 2018

National

Finished
  • Identification of new treatment options in refractory testicular germ cell tumors
    Program: SRDA
    Duration: 1. 7. 2021 – 30. 6. 2025
  • Identification of potential therapeutic targets associated with cisplatin resistance in yolk sac tumors
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Mechanism of the mesenchymal stromal cell-induced tolerance to antitumor treatment and targeted therapeutic intervention in the breast cancer cells
    Program: SRDA
    Duration: 1. 7. 2017 – 31. 12. 2021
  • Identification and validation of signalling pathways associated with circulating tumor cells in breast cancer
    Program: SRDA
    Duration: 1. 7. 2017 – 30. 6. 2021
  • Cellular and molecular traits of human metastasis-initiating cells at different stages of metastasis development.
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • Therapeutic targeting of cancer stem cell markers circumventing cisplatin resistance in testicular germ cell tumors
    Program: Other projects
    Duration: 1. 12. 2018 – 31. 12. 2020
  • The role of CA IX in adaptation to tumor microenvironment and in resistance to anticancer therapy: molecular mechanisms and clinical implications
    Program: SRDA
    Duration: 1. 7. 2016 – 31. 12. 2020
  • Role of Stress Response Induced in Mesenchymal Stromal Cells in Extrinsic Drug Resistance of Human Tumor Cells
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Mechanisms of interactions and bystander effect mediated by mesenchymal stromal cells expressing prodrug-converting genes on tumour stem cells
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 9. 2017
  • Cytotoxic Effect of Engineered Mesenchymal Stromal Cells on Human Chemoresistant Tumour Cells and Cancer Stem Cells
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • -
    Program: Other projects
    Duration: 1. 1. 2016 – 31. 12. 2016
  • Targeted Augmented Cellular Therapy against Tumor Initiating and Chemoresistant Cells
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2015
  • Molecular mechanisms of tumor-driven mesenchymal stromal cells‘ differentiation
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2014
  • Chemoresistance abrogation in human cancer stem cells by inhibition of ALDH1A1 enzyme
    Program: Other projects
    Duration: 1. 7. 2012 – 30. 6. 2013
  • Study of interactions between tumour cells and mesenchymal stem cells carrying suicide genes.
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2012
  • Modification of biological properties in mammary malignant cells
    Program: Other projects
    Duration: 1. 6. 2011 – 31. 12. 2011
  • Human mesenchymal stem cells as cytoreagents for metastasis-targeted therapy
    Program: SRDA
    Duration: 1. 6. 2008 – 30. 6. 2011
  • Interaction of human adipose-tissue derived mesenchymal stem cells with human cancer cells
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
Employees